Zobrazeno 1 - 10
of 178
pro vyhledávání: '"CRISPR-screens"'
Autor:
Simin Wang, Yangjie Xiong, Yuxiang Luo, Yanying Shen, Fengrui Zhang, Haoqi Lan, Yuzhi Pang, Xiaofang Wang, Xiaoqi Li, Xufen Zheng, Xiaojing Lu, Xiaoxiao Liu, Yumei Cheng, Tanwen Wu, Yue Dong, Yuan Lu, Jiujie Cui, Xiaona Jia, Sheng Yang, Liwei Wang, Yuexiang Wang
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 5, Pp 1115-1142 (2024)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an overall 5-year survival rate of
Externí odkaz:
https://doaj.org/article/abb29ed6ca354abcb56f3459b63f402e
Autor:
Sowmya S. V., Dominic Augustine, Shazia Mushtaq, Hosam Ali Baeshen, Heba Ashi, Reem Nabil Hassan, Mohammed Alshahrani, Shankargouda Patil
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
This review presents an in-depth analysis of the immense potential of CRISPR-Cas9 technology in revolutionizing oral cancer research. It underscores the inherent limitations of conventional treatments while emphasizing the pressing need for groundbre
Externí odkaz:
https://doaj.org/article/51319f908dda44c9b32c716869f3bc46
Autor:
Tian Lin, Dan Liu, Zhangchun Guan, Xuan Zhao, Sijin Li, Xu Wang, Rui Hou, Junnian Zheng, Jiang Cao, Ming Shi
Publikováno v:
Heliyon, Vol 10, Iss 8, Pp e29382- (2024)
CRISPR-based screens have discovered novel functional genes involving in diverse tumor biology and elucidated the mechanisms of the cancer pathological states. Recently, with its randomness and unbiasedness, CRISPR screens have been used to discover
Externí odkaz:
https://doaj.org/article/1681110421ae473aa1a9da32d8de390d
Publikováno v:
BMC Biology, Vol 21, Iss 1, Pp 1-25 (2023)
Abstract Background TP53 is a master tumor suppressor gene, mutated in approximately half of all human cancers. Given the many regulatory roles of the corresponding p53 protein, it is possible to infer loss of p53 activity – which may occur due to
Externí odkaz:
https://doaj.org/article/0e83e71c9c774af0b871e2049e79e55c
Publikováno v:
BMC Biology, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background CRISPR-based screens are revolutionizing drug discovery as tools to identify genes whose ablation induces a phenotype of interest. For instance, CRISPR-Cas9 screening has been successfully used to identify novel therapeutic target
Externí odkaz:
https://doaj.org/article/fc7023cd3c3843d6bcb498ae4d8ae1e3
Autor:
Katherine Chan, Adrian Granda Farias, Hunsang Lee, Furkan Guvenc, Patricia Mero, Kevin R. Brown, Henry Ward, Maximilian Billmann, Kamaldeep Aulakh, Audrey Astori, Shahan Haider, Edyta Marcon, Ulrich Braunschweig, Shuye Pu, Andrea Habsid, Amy Hin Yan Tong, Natasha Christie-Holmes, Patrick Budylowski, Ayoob Ghalami, Samira Mubareka, Finlay Maguire, Arinjay Banerjee, Karen L. Mossman, Jack Greenblatt, Scott D. Gray-Owen, Brian Raught, Benjamin J. Blencowe, Mikko Taipale, Chad Myers, Jason Moffat
Publikováno v:
Heliyon, Vol 9, Iss 1, Pp e12744- (2023)
SARS-CoV-2 depends on host cell components for infection and replication. Identification of virus-host dependencies offers an effective way to elucidate mechanisms involved in viral infection and replication. If druggable, host factor dependencies ma
Externí odkaz:
https://doaj.org/article/1fc0974096af4f23af93d99b3d0085a0
Publikováno v:
BMC Genomics, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Single-cell CRISPR screens are powerful tools to understand genome function by linking genetic perturbations to transcriptome-wide phenotypes. However, since few cells can be affordably sequenced in these screens, biased sampling
Externí odkaz:
https://doaj.org/article/397006fadd80408ea78a4a7d031b18b7
Autor:
Zhongguo Zhou, Can Tao, Jianting Li, Johnny Cheuk-on Tang, Albert Sun-chi Chan, Yuanyuan Zhou
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chimeric antigen receptor T cell (CAR-T) therapy is novel tumor immunotherapy that enables autologous T to express synthetic receptors to specifically recognize the surface tumor-associated antigens for exerting subsequent antitumor effects, and elim
Externí odkaz:
https://doaj.org/article/ba86be926fec4392931165044e45861e
Autor:
Chaozheng Xie, Kang Li, Ya Li, Xudong Peng, Biyun Teng, Kuan He, Aishun Jin, Wang Wang, Zhengqiang Wei
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The first-line anticancer agent oxaliplatin (OXL) is the preferred drug for treating colorectal cancer (CRC); however, the development of drug resistance is common in patients treated with OXL, which considerably reduces the efficacy of OXL-based reg
Externí odkaz:
https://doaj.org/article/9f2bd82731a84fbab9daf526578a7993
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.